Please login to the form below
Gyroscope
This page shows the latest Gyroscope news and features for those working in and with pharma, biotech and healthcare.
Novartis to pay up to $1.5bn for Gyroscope
Swiss pharma Novartis is set to buy UK-based gene therapy company, Gyroscope Therapeutics, for an upfront payment of $800m and another $700m in milestone payments. ... Gyroscope is a clinical-stage gene therapy company working on eye diseases that cause
Latest news
-
Life sciences and NHS feature in Johnson speech – but Brexit promises predominate
This was an apparent reference to Gyroscope, the company based in the Stevenage biotech cluster near London, which is testing its gene therapy for advanced dry Age-related Macular Degeneration (AMD).
-
$450m diagnostics sale will fuel more Syncona biotech funding
This will help frees up its portfolio for new investments. Since 31 March 2019, Syncona has invested £64.1min to its portfolio companies, including gene therapy companies Freeline and Gyroscope and
-
Syncona launches another cell therapy company, Treg specialist Quell
Quell is the tenth life science company founded by Syncona, with other UK-based cell and gene therapy companies on its roster including Gyroscope and Freeline.
-
Gyroscope advances gene therapy platform, merges with Orbit
News mirrors Ocugen and Histogenics merger. UK-based Gyroscope is to merge with Orbit Biomedical to further develop its gene therapy platform for eye diseases. ... will hopefully cure eye diseases that today leave people blind,” said Gyroscope’s
-
Novartis and Syncona back new Swiss biotech Anaveon
These include Freeline, which last year raised £88m to accelerate haemophilia gene therapy, and Gyroscope, which earlier this month dosed its first patient with its gene therapy for dry AMD, and
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
25 Women Leaders in UK Healthcare
Women trailblazers helping to shape the future of healthcare (Part 1)
-
25 Women Leaders in UK Healthcare (part 2)
One notable exception to that is Soraya Bekkali, president, head of R&D at Gyroscope, a UK firm developing gene therapies for eye diseases. ... Between 2017 and March 2019 Soraya served as CEO and CMO of Gyroscope and led the company successfully to
-
Wearables: the tangible product of the patient revolution
Exact details remain vague, but Apple said in a statement that researchers would be able to ask for access to the accelerometer, microphone, gyroscope and GPS sensors in the iPhone “to
More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Gyroscope Therapeutics appoints CEO
Dr Soraya Bekkali joins from biotech firm Lysogene. Ophthalmology group Gyroscope Therapeutics has appointed Dr Soraya Bekkali as its chief executive officer and director of its board. ... Gyroscope has a unique translational approach to tackling complex
-
Anne Prener to lead Freeline Therapeutics
She joins from Gyroscope Therapeutics to take up CEO role. London, UK-based gene therapy-focused biopharmaceutical company Freeline Therapeutics has appointed Anne Prener as its new chief executive officer. ... Prior to Gyroscope, Frener served as vice
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Wearable Technology Show 2016 report: wearables that could change healthcare, by Andy Hastie
The glasses connect wirelessly with compatible smartphones and are equipped with an accelerometer, gyroscope, electronic compass, brightness sensor, microphone and camera.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
